🇺🇸 FDA
Patent

US 11327083

Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome

granted A61PA61P5/38

Quick answer

US patent 11327083 (Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome) held by Corcept Therapeutics Incorporated expires Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Corcept Therapeutics Incorporated
Grant date
Tue May 10 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
29
CPC classes
A61P, A61P5/38